NCT05402306 is a NA clinical trial of Treatment group in Anxiety Disorders, sponsored by University of Oslo.

Who is sponsoring NCT05402306?

NCT05402306 is sponsored by University of Oslo.

What drugs are being tested in NCT05402306?

Interventions in NCT05402306: Treatment group.

What condition does NCT05402306 study?

NCT05402306 studies Anxiety Disorders.

Is NCT05402306 still recruiting?

NCT05402306 is currently status unknown. Last updated 2 June 2022.

Last reviewed 2022-06-02 · How we verify

NCT05402306

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Feasibility and Efficacy of a Two-week MCT Treatment of Anxiety Disorders in a Group Setting

Status unknown NA Last updated 2 June 2022

What this trial tests

NA trial testing Treatment group in Anxiety Disorders in 60 participants. Status unknown.

Timeline

28 February 2022

Primary endpoint
28 January 2023

28 January 2023

Quick facts

Lead sponsor	University of Oslo
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	28 February 2022
Primary completion	28 January 2023
Estimated completion	28 January 2023
Sites	1 location across Norway

Drugs / interventions tested

Treatment group

Conditions studied

Anxiety Disorders — all drugs for Anxiety Disorders →

Sponsor

University of Oslo

Who can join

Adults 18 to 30, any sex, with Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Long treatment durations may not always be feasible for patients due to pressure to get better quickly, long travel distance to treatment clinics, inflexible working hours, or childcare. To overcome these challenges intensive treatments are currently emerging and several research studies have shown significant and lasting results of diagnosis-specific intensive treatments. A transdiagnostic treatment in a group setting can contribute to a more efficient course of treatment for patients. Research suggests that Metacognitive Therapy (MCT) is an effective treatment for anxiety disorders. However, MCT has not previously been used on inpatients over a two-week period. To make the treatment tangible for patients and easy to administer for therapists over a short time, attention training technique (ATT) will mainly be used as a changing technique. The main aim of the study is to explore the feasibility and efficacy of intensive and short-term MCT for anxiety disorders in a group setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Treatment group

Trials testing the same drug.

NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting
NCT06858969 — Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
NCT05697679 — Effects of Physical Activiy Promotion Intervention Programs in Emerging Adulthood · NA · completed
NCT04597008 — Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA · Phase 3 · completed
NCT05521282 — The Efficacy of Qianglidingxuan Tablets in the Treatment of Hypertension · Phase 4 · completed

Other recruiting trials for Anxiety Disorders

Currently open trials in the same condition.

NCT07340281 — Biomarkers for Exercise · NA · recruiting
NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting

Other University of Oslo trials

Trials by the same sponsor.

NCT07346911 — Digital Interventions for Relapse Prevention in Adolescence · NA · not yet recruiting
NCT07499219 — Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological Trea · NA · not yet recruiting
NCT07408687 — Mechanisms Of Change in Psychotherapy: The Effects of Cognitive Behavioral Therapy and Psychodynamic Therapy in Once - V · NA · not yet recruiting
NCT07287072 — Pain Reprocessing Therapy for Chronic Primary Pain · NA · not yet recruiting
NCT07428694 — From Bench to Bedside: A Machine Learning Tool for the Detection of Inspiratory Leak · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05402306 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oslo
Last refreshed: 2 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402306.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing